BRIGHT ANGEL THERAPEUTICS
Bright Angel Therapeutics is a developer of novel therapeutics designed to provide treatment of drug-resistant and life-threatening fungal infections. The company's services increases efficacy of current treatments and eradicates drug resistance by targeting the stress responses required by fungi for survival, virulence and drug resistance, enabling users to overcome the frequent emergence of clinical resistance largely responsible for the severe morbidity and mortality associated with infection by diverse fungal pathogens.
BRIGHT ANGEL THERAPEUTICS
Industry:
Biotechnology
Founded:
2016-01-01
Address:
Toronto, Ontario, Canada
Country:
Canada
Website Url:
http://www.brightangeltherapeutics.com
Total Employee:
1+
Status:
Active
Total Funding:
0
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt Content Delivery Network Euro Google Apps For Business GoDaddy DNS Typekit
Similar Organizations
Chaperone Therapeutics
Chaperone Therapeutics is developing frontline therapies to address diseases of protein misfolding
Investors List
Schrödinger
Schrödinger investment in Seed Round - Bright Angel Therapeutics
MaRS Investment Accelerator Fund
MaRS Investment Accelerator Fund investment in Seed Round - Bright Angel Therapeutics
Viva BioInnovator
Viva BioInnovator investment in Seed Round - Bright Angel Therapeutics
adMare Bio Innovations
adMare Bio Innovations investment in Seed Round - Bright Angel Therapeutics
Lumira Ventures
Lumira Ventures investment in Seed Round - Bright Angel Therapeutics
UTEST
UTEST investment in Pre Seed Round - Bright Angel Therapeutics
Official Site Inspections
http://www.brightangeltherapeutics.com
- Host name: 198.185.159.144
- IP address: 198.185.159.144
- Location: New York United States
- Latitude: 40.7157
- Longitude: -74
- Metro Code: 501
- Timezone: America/New_York
- Postal: 10013
More informations about "Bright Angel Therapeutics"
Management Team — Bright Angel Therapeutics
Leah Cowen, Ph.D. | Co-founder and CSO . Leah Cowen is Vice President, Research at the University of Toronto (UofT), Professor in the Department of Molecular Genetics, co-Director of the CIFAR Fungal Kingdom: Threats & …See details»
Board of Directors — Bright Angel Therapeutics
Beni Rovinski, Ph.D. | Chairman of the Board. Dr. Benjamin Rovinski has 30 years of investment, operational, managerial and research experience in the healthcare sector.See details»
Bright Angel Therapeutics - Crunchbase Company …
Bright Angel Therapeutics is a developer of novel therapeutics designed to provide treatment of drug-resistant and life-threatening fungal infections.See details»
Bright Angel Therapeutics - PitchBook
Jan 1, 2016 Bright Angel Therapeutics General Information Description. Developer of antifungal resistance drugs designed to treat life-threatening fungal infections. The company's drugs help …See details»
Bright Angel Therapeutics | Source From Ontario
Bright Angel Therapeutics (BAT) is a pre-clinical stage biotechnology company focused on the development of novel therapeutics for the treatment of drug-resistant and life-threatening …See details»
Bright Angel Therapeutics Inc. - University of Toronto …
Bright Angel combines the expertise of world-renowned mycology experts with Schrödinger’s cutting-edge computational technology to develop innovative therapeutics for the treatment of …See details»
Bright Angel Therapeutics - LinkedIn
Bright Angel Therapeutics is a Toronto based company focused on tackling the problem of resistance to current antifungal therapies via the development of new drugs that can prevent …See details»
Bright Angel Therapeutics - Overview, News & Similar ... - ZoomInfo
Who is Bright Angel Therapeutics. Bright Angel Therapeutics is a Toronto-based, pre-clinical company committed to developing new drugs to address the growing global public health cr …See details»
Dec 21, 2017 — Bright Angel Therapeutics
Dec 21, 2017 New York, NY and Toronto Canada, Dec. 21, 2017 (GLOBE NEWSWIRE) -- Schrödinger, Inc., a privately-held company dedicated to revolutionizing drug discovery …See details»
Bright Angel Therapeutics | Viva BioInnovator
Www.brightangeltherapeutics.com. location. Canada, Ontario, Toronto. modality. Small Molecule. Indications. Infectious. Bright Angel Therapeutics is a pre-clinical stage biotechnology …See details»
Bright Angel Therapeutic Inc Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Bright Angel Therapeutic Inc of Toronto, ON. Get the latest business insights from Dun & Bradstreet.See details»
Contact - Bright Angel Therapeutics
If you want to learn more about Bright Angel Therapeutics, please email us at: [email protected]. Bright Angel Therapeutics in located in the MaRS …See details»
Bright Angel Therapeutics Announces New Funding to Advance …
Dec 3, 2019 TORONTO, ON / ACCESSWIRE / December 3, 2019 / Bright Angel Therapeutics, a biotechnology company focused on developing novel antifungal drugs, today announced an …See details»
Bright Angel Therapeutics Announces New Funding to Advance …
Bright Angel Therapeutics Announces New Funding to Advance Therapies for Invasive Fungal Infections. TORONTO, ON / ACCESSWIRE / December 3, 2019 / Bright Angel Therapeutics, …See details»
Bright Angel Therapeutics Announces New Funding to Advance …
Dec 3, 2019 TORONTO, ON / ACCESSWIRE / December 3, 2019 / Bright Angel Therapeutics, a biotechnology company focused on developing novel antifungal drugs, today announced an …See details»
Launch of Bright Angel Therapeutics – TIAP
New York, NY and Toronto Canada, Dec. 21, 2017 (GLOBE NEWSWIRE) — Schrödinger, Inc., a privately-held company dedicated to revolutionizing drug discovery through advanced …See details»
New Bright Angel for Developing Antifungal Drugs
Jan 26, 2018 Launch of the company was made possible by partnering with Schrödinger, Inc., a privately-held company dedicated to revolutionizing drug discovery through advanced …See details»
Pipeline - Bright Angel Therapeutics
Pipeline. Bright Angel Therapeutic’s pipeline is comprised of novel treatment approaches for the eradication of drug-resistant and life-threatening invasive fungal infections.See details»
Bright Angel Therapeutics Announces New Funding to Advance …
Dec 3, 2019 TORONTO – Bright Angel Therapeutics, a biotechnology company focused on developing novel antifungal drugs, today announced an extension to their seed financing …See details»